Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979236 | 0.86 | TLR7 (0.41) | TLR7LMNAALDH1A1NPY5RTLR8 | |
| SCHEMBL2512664 | 0.85 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL11917592 | 0.85 | TLR7 (0.52) | TLR7TLR8 | |
| SCHEMBL9979421 | 0.83 | ALDH1A1 (0.33) | LMNAGAAALDH1A1NPY5RSLC6A9 | |
| SCHEMBL9979167 | 0.83 | TLR7 (0.42) | TLR7TLR8 | |
| SCHEMBL9979161 | 0.79 | TLR7 (0.44) | TLR7TLR8 | |
| SCHEMBL2513263 | 0.79 | TLR7 (0.39) | TLR7TLR8 | |
| SCHEMBL11917349 | 0.77 | TLR7 (0.37) | TLR7ALDH1A1TLR8KMT2A | |
| SCHEMBL2515287 | 0.77 | TLR7 (0.37) | TLR7ALDH1A1TLR8KMT2A | |
| SCHEMBL2514666 | 0.77 | TLR7 (0.42) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350034-B2 | Substituted chiral fused [1,2]imidazo[4,5-C] ring compounds | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-08 | — | — | US | claimed |
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMANY | 2011-12-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110293654-A1 | SUBSTITUTED CHIRAL FUSED [1,2]IMIDAZO[4,5-c] RING COMPOUNDS | IFNG, IL4, IFNAR1 | TLR7 171/4885LMNA 4409/4885GAA 3201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.